| Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis. | |
| | |
MedLine Citation:
|
PMID: 21775220 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cystic fibrosis (CF) patients suffer typically from bacterial infections of their airways. Whilst current antibiotic-based treatment of these infections has brought much benefit to patients, it has been difficult to make either direct or indirect assessments of the in vivo efficacy of any specific treatment used. Traditional culture-based assessment has for example been rarely used to determine the direct impact of therapy on the bacteria in the airways. Instead, the "success" of a treatment is most often gauged through measures of respiratory and general health. New culture-independent approaches though are emerging that offer much promise here however in allowing a more comprehensive evaluation of antimicrobial efficacy. These new methods offer an opportunity to examine bacterial outcomes rather than host outcomes alone. Application of these novel techniques in a systematic way will lead to the rationalisation and, likely greater still individualisation, of therapy for CF patients. This review discusses host and microbiological factors that may influence antibiotic efficacy. Moreover, the degree to which the inherent complexity of CF respiratory infections complicates the process of determining treatment impact and the need to identify more robust microbiological outcome measures will also be reviewed. |
| | |
Authors:
|
Geraint B Rogers; Lucas R Hoffman; Gerd Döring |
Publication Detail:
|
Type: Journal Article; Review Date: 2011-07-19 |
Journal Detail:
|
Title: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society Volume: 10 ISSN: 1873-5010 ISO Abbreviation: J. Cyst. Fibros. Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-11-21 Completed Date: 2012-04-02 Revised Date: 2013-03-18 |
Medline Journal Info:
|
Nlm Unique ID: 101128966 Medline TA: J Cyst Fibros Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 387-400 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved. |
Affiliation:
|
Molecular Microbiology Research Laboratory, King's College London, United Kingdom. geraint.rogers@kcl.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Bacterial Agents
/
therapeutic use* Bacteria / genetics Bacterial Infections / drug therapy*, etiology* Chronic Disease Cystic Fibrosis / complications* Evaluation Studies as Topic Humans Lung Diseases / drug therapy*, microbiology* Respiratory Tract Infections / drug therapy*, etiology* |
| Grant Support | |
ID/Acronym/Agency:
|
UL1 RR025014/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical outcomes of the REALIZE adjustable gastric band-C at one year in a U.S. population.
Next Document: On-line coupling of dynamic microwave-assisted extraction with high-speed counter-current chromatogr...